Clinical Trial Update: An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs

View source ↗

Summary

An observational study of tocilizumab (RoActemra/Actemra) in rheumatoid arthritis patients who had an inadequate response to DMARDs has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Status: COMPLETED